Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

Key Points Net revenue (GAAP) dropped 18.1% year-over-year in Q2 2025, as reimbursement pressure continued to impact results despite increased unit sales for DEXTENZA. Research and development ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

One United Properties (BVB: ONE), the leading Romanian green developer of residential, mixed-use, and office properties, recorded total sales and pre-sales of EUR 95.4 million in H1 2025, ...

Having built a strong foothold in Rajasthan with landmark developments and expanding its footprint into the Delhi-NCR market, ...

El Pollo Loco is working through a choppy sales environment, with guests feeling limited on what they can spend. Even with ...

Discover key insights from Neurocrine Biosciences' Q2 2025 earnings, featuring record INGREZZA growth, CRENESSITY's rapid adoption, and strategic ...

Dubai’s off-plan branded residences are taking centre stage in the luxury property market, accounting for 83 per cent of ...

Pipeline Regulatory Progress -- Two risk-adjusted product launches (AMP-002 and AMP-015) are included in the flat full-year ...

President Donald Trump's administration and its allies have pushed aggressively for drilling, mining and logging in Alaska.

Discover key takeaways from Altisource's Q2 2025 earnings, including 11% service revenue growth, improved net income, and a strong sales pipeline.